ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

This study is looking for adult participants, aged 18 or older.

To be considered, you must have a specific type of lung cancer called unresectable Stage III non-small cell lung cancer. "Unresectable" means the cancer can't be completely removed by surgery because of its size or location. "Stage III" means it's in your chest but hasn't spread to distant parts of your body. You must have also completed treatment with a combination of chemotherapy and radiation therapy at the same time, and importantly, your cancer must not have grown worse since that treatment finished.

There will be other detailed medical checks to make sure this study is safe and appropriate for you, but generally, both men and women are welcome to participate.

If you join this study, you would be randomly assigned to receive either the new medicine (pumitamig) or the standard medicine (durvalumab). This means you wouldn't get to choose which one you receive, similar to flipping a coin. You wouldn't know which medicine you're getting, but your study doctor would. You would receive one of these medicines as a drip into your arm (an infusion) for a set period.

Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and scans (like CT or MRI scans) to see how the treatment is working and to monitor your health. You will also be asked about any side effects you might be experiencing. These visits will continue for as long as the treatment is helping, and then you'll enter a follow-up period where you'll have fewer visits, but doctors will still keep in touch to see how you're doing. The total length of your participation will depend on how you respond to the treatment, but follow-up can last for several years.